Innova Captab
Innova Captab Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Innova Captab expects continued growth driven by existing volume growth and the new Jammu facility. The Jammu facility, operational from January 14, 2025, is expected to drive significant incremental revenue growth, targeting ₹400 to ₹500 crores in FY '26 and aiming for ₹1,000 crores in 2-3 years.
From Innova Captab's Q3 FY25 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- Innova Captab expects continued growth driven by existing volume growth and the new Jammu facility.
- Jammu facility revenue is estimated between ₹400-₹500 crores in FY '26, with potential to reach ₹1,000 crores in 2-3 years.
- Peak utilization for Jammu plant expected around 70-75%, with potential peak revenue near ₹1,500-₹2,000 crores.
- Overall company growth, including Jammu, is anticipated at 25%+ for FY '26.
- CDMO business has shown a strong CAGR of 20%+, expected to sustain early teens growth despite pricing pressure.
- Domestic and international generic businesses continue to expand, with international growing 17% YoY.
- Sharon Bio-Medicines forecasted to grow in early teens over the coming years.
2 more points from Innova Captab's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Innova Captab said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Innova Captab has recently commercialized its Jammu facility in January 2025, representing a significant capital investment.
- The Jammu facility is expected to generate incremental revenue of ₹400-500 crores in FY26, ramping up further to peak utilization by FY28.
- The company is focused on expanding capacity and product portfolio through this new facility, with an estimated peak revenue potential of around ₹2,000 crores at full utilization.
- The Jammu facility is compliant with stringent future-ready regulations, designed with a 40-50 year vision.
2 more points from Innova Captab's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Innova Captab said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The management is still working with the Business Development (BD) team on finalizing the order book for the Jammu facility.
- Estimated revenue for Jammu in Q4 is expected to be in the range of ₹20 crores to ₹40 crores.
- Some orders from the Sharon business were deferred from Q3 to Q4, estimated around ₹4-5 crores.
- Overall, the Jammu facility is ramping up with commercial operations starting January 2025.
- There is ongoing effort to maximize sales and mitigate any EBITDA costs from the new Jammu facility ramp-up.
2 more points from Innova Captab's call on order book
Pro opens every point from 15K+ earnings calls
Innova Captab — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹448 Cr, net profit ₹38 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Innova Captab Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- SMS Pharma. (Q3 FY25)
Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Wockhardt (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…
- NGL Fine Chem (Q3 FY25)
Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Key concall takeaways from NGL Fine Chem Ltd's Q3 FY25…
- Shree Ganesh Rem (Q3 FY25)
Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…
Arthneeti Pro · Annual
Innova Captab and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Innova Captab Q3 FY25 results?
Innova Captab expects continued growth driven by existing volume growth and the new Jammu facility. The Jammu facility, operational from January 14, 2025, is expected to drive significant incremental revenue growth, targeting ₹400 to ₹500 crores in FY '26 and aiming for ₹1,000 crores in 2-3 years.
What is Innova Captab share price analysis?
Innova Captab currently shows a neutral. The stock trades at a P/E of 40.4 with a market cap of ₹6,229 Cr. Investors should review the full earnings analysis for detailed insights.
Is Innova Captab planning capital expenditure?
Innova Captab has recently commercialized its Jammu facility in January 2025, representing a significant capital investment.
Keep Innova Captab on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.